Investor Alert

The Ratings Game Archives | Email alerts

Aug. 18, 2021, 11:22 a.m. EDT

Analysts upbeat on Tilray’s U.S. prospects after MedMen deal

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Tilray Inc. Cl 2 (TLRY)
  • X
    Tilray Inc. (TLRY)
  • X
    MedMen Enterprises Inc. (MMNFF)

or Cancel Already have a watchlist? Log In

Steve Gelsi

Shares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company’s announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.

Gotham Green Partners, a backer of MedMen, is the seller on the deal.

Tilray’s stock /zigman2/quotes/209129655/composite TLRY -4.15% /zigman2/quotes/226578748/delayed CA:TLRY -3.99% shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen /zigman2/quotes/201940908/composite MMNFF -1.59% , which trade over the counter, climbed 25.2%.

Don’t miss : Tilray eyes U.S. cannabis market with MedMen deal, stock gains .

Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen’s current footprint includes dispensaries in New York and California.

“While an equity interest in a larger multi-state operator (MSO) would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,” Grey wrote in a research note.

He maintained his neutral rating on Tilray.

Also read : Tilray and Aphria merger closes and creates world’s biggest week company by revenue .

Meanwhile, Oppenheimer & Co.’s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a “meaningful” contribution from the U.S. market.

“We continue to look favorably upon management’s efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,” Parikh said.”

Tilray’s stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF /zigman2/quotes/213173823/composite THCX -2.45% has gained 14.0% this year while the S&P 500 index /zigman2/quotes/210599714/realtime SPX -0.11% has advanced 18.3%.

US : U.S.: Nasdaq
$ 11.08
-0.48 -4.15%
Volume: 18.84M
Oct. 22, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$5.36 billion
Rev. per Employee
CA : Canada: Toronto
$ 13.73
-0.57 -3.99%
Volume: 1.42M
Oct. 22, 2021 5:00p
P/E Ratio
Dividend Yield
Market Cap
$6.60 billion
Rev. per Employee
US : U.S.: OTC
$ 0.27
-0.0043 -1.59%
Volume: 2.01M
Oct. 22, 2021 3:59p
P/E Ratio
Dividend Yield
Market Cap
$212.14 million
Rev. per Employee
US : U.S.: NYSE Arca
$ 12.32
-0.31 -2.45%
Volume: 52,745
Oct. 22, 2021 4:10p
-4.88 -0.11%
Volume: 1.82B
Oct. 22, 2021 5:04p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.